Content area
Full Text
Surprise, surprise: Impax Labs, looking to bulk up amid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal.
On Tuesday, the company said it had inked an all-stock pact to merge with Amneal in a transaction that would make it the fifth-largest U.S. generics player. The move will hand Impax shareholders 25% of the new company-which will take Amneal’s name and have an expected value of $6.4 billion, The Wall Street Journal says-while Amneal’s owners will control the rest.
Those Impax shareholders weren’t too...